DK1107974T3 - Nye hydratformer af alendronat natrium, processer til fremstilling deraf, og farmaceutiske sammensætninger deraf - Google Patents

Nye hydratformer af alendronat natrium, processer til fremstilling deraf, og farmaceutiske sammensætninger deraf

Info

Publication number
DK1107974T3
DK1107974T3 DK99944004T DK99944004T DK1107974T3 DK 1107974 T3 DK1107974 T3 DK 1107974T3 DK 99944004 T DK99944004 T DK 99944004T DK 99944004 T DK99944004 T DK 99944004T DK 1107974 T3 DK1107974 T3 DK 1107974T3
Authority
DK
Denmark
Prior art keywords
processes
alendronate sodium
pharmaceutical compositions
preparation
new
Prior art date
Application number
DK99944004T
Other languages
Danish (da)
English (en)
Inventor
Ramy Lidor-Hadas
Nina Finkelstein
Judith Aronhime
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Application granted granted Critical
Publication of DK1107974T3 publication Critical patent/DK1107974T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DK99944004T 1998-08-27 1999-08-27 Nye hydratformer af alendronat natrium, processer til fremstilling deraf, og farmaceutiske sammensætninger deraf DK1107974T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9831398P 1998-08-27 1998-08-27
US12974399P 1999-04-16 1999-04-16
US14446199P 1999-07-19 1999-07-19

Publications (1)

Publication Number Publication Date
DK1107974T3 true DK1107974T3 (da) 2006-10-30

Family

ID=27378576

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99944004T DK1107974T3 (da) 1998-08-27 1999-08-27 Nye hydratformer af alendronat natrium, processer til fremstilling deraf, og farmaceutiske sammensætninger deraf

Country Status (30)

Country Link
US (2) US6281381B1 (enExample)
EP (1) EP1107974B1 (enExample)
JP (2) JP2002523514A (enExample)
KR (2) KR20070034132A (enExample)
AT (1) ATE334993T1 (enExample)
AU (1) AU5698899A (enExample)
BG (1) BG65329B1 (enExample)
BR (1) BR9913472A (enExample)
CA (1) CA2341459A1 (enExample)
CZ (1) CZ2001629A3 (enExample)
DE (1) DE69932620T2 (enExample)
DK (1) DK1107974T3 (enExample)
EA (1) EA002739B1 (enExample)
EE (1) EE04552B1 (enExample)
ES (1) ES2270613T3 (enExample)
HR (1) HRP20010129A2 (enExample)
HU (1) HUP0203078A3 (enExample)
IL (1) IL141423A (enExample)
IS (1) IS5864A (enExample)
LT (1) LT4888B (enExample)
LV (1) LV12720B (enExample)
NO (1) NO20010957L (enExample)
NZ (1) NZ510682A (enExample)
PL (1) PL346347A1 (enExample)
PT (1) PT1107974E (enExample)
RO (1) RO122854B1 (enExample)
SI (1) SI20581B (enExample)
SK (1) SK2482001A3 (enExample)
WO (1) WO2000012517A1 (enExample)
YU (1) YU14701A (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1406910B1 (fr) * 2001-07-16 2010-01-13 Universite Paris 13 Procedes de preparation de derives de bisphosphonates
GB2383042A (en) * 2001-10-18 2003-06-18 Cipla Ltd Amorphous alendronate sodium
US20040052843A1 (en) * 2001-12-24 2004-03-18 Lerner E. Itzhak Controlled release dosage forms
HUP0600680A3 (en) * 2001-12-24 2008-04-28 Teva Pharma Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material, and process and tooling for producing it
ITMI20020146A1 (it) * 2002-01-29 2003-07-29 Lyogen Ltd Alendronato monosodico amorfo e processo per la sua preparazione
JP2005531532A (ja) * 2002-04-05 2005-10-20 メルク　エンド　カムパニー　インコーポレーテッド アレンドロナートおよびビタミンｄ製剤を用いる骨吸収阻害法
US20080249068A1 (en) * 2002-09-05 2008-10-09 Deluca Hector F Method of Extending the Dose Range of Vitamin D Compounds
WO2005035542A1 (en) * 2003-10-14 2005-04-21 Pliva-Istrazivanje I Razvoj D.O.O. Solid-state form of alendronate sodium and preparation thereof
US20050181043A1 (en) * 2004-02-12 2005-08-18 Indranil Nandi Alendronate salt tablet compositions
US20050261250A1 (en) * 2004-05-19 2005-11-24 Merck & Co., Inc., Compositions and methods for inhibiting bone resorption
DK1753395T3 (da) 2004-05-24 2010-11-08 Warner Chilcott Co Llc Enterisk, fast, oral doseringsform af et bisphosphonat, der indeholder et chelateringsmiddel
CZ296937B6 (cs) * 2004-09-02 2006-07-12 Zentiva, A. S Trisodná sul kyseliny 4-amino-1-hydroxybutyliden-1,1-bisfosfonové
ES2331015T3 (es) * 2004-10-29 2009-12-18 Sandoz Ag Proceso para la preparacion de un glatiramero.
US20060134190A1 (en) * 2004-12-16 2006-06-22 Banner Pharmacaps Inc. Formulations of bisphosphonate drugs with improved bioavailability
CZ297262B6 (cs) * 2004-12-28 2006-10-11 Zentiva, A. S. Trisodná sul kyseliny 4-amino-1-hydroxybutyliden-1,1-bisfosfonové
US8003820B2 (en) * 2005-10-20 2011-08-23 Dr. Reddy's Laboratories Limited Process for preparing bisphosphonic acids
AR058168A1 (es) * 2005-11-07 2008-01-23 Merck & Co Inc Sintesis del alendronato de sodio trihidratado
NZ589053A (en) * 2006-10-27 2012-03-30 Signal Pharm Llc Process of preparing 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol compounds
JP5244608B2 (ja) * 2006-11-22 2013-07-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 二糖類化合物のナトリウム塩及びその製造方法並びにその使用
US20090118238A1 (en) * 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090076144A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched bazedoxifene
US20090170815A1 (en) * 2007-12-28 2009-07-02 Roxane Laboratories Incorporated. Alendronate oral liquid formulations
US8629178B2 (en) * 2009-11-03 2014-01-14 Li Liu Sodium tanshinone IIA sulfonate hydrate and preparation method and use thereof
SG10202012791TA (en) 2013-11-15 2021-01-28 Akebia Therapeutics Inc Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3016289A1 (de) 1980-04-28 1981-10-29 Henkel KGaA, 4000 Düsseldorf Verfahren zur herstellung von omega -amino-1-hydroxyalkyliden-1,1-bis-phosphonsaeuren
IT1201087B (it) 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
US4639338A (en) * 1984-08-06 1987-01-27 Ciba-Geigy Corporation Preparation of crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate pentahydrate
DE3434667A1 (de) 1984-09-21 1986-04-03 Henkel KGaA, 4000 Düsseldorf 4-dimethylamino-1-hydroxybutan-1,1-diphosphonsaeure, deren wasserloesliche salze, verfahren zu ihrer herstellung sowie ihre verwendung
IT1196315B (it) * 1984-10-29 1988-11-16 Gentili Ist Spa Procedimento per la preparazione di acidi difosfonici
US4711800A (en) * 1985-06-06 1987-12-08 Divincenzo Maureen Needlecraft with metallic substrate
US4922007A (en) * 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
US5019651A (en) * 1990-06-20 1991-05-28 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
US5039819A (en) 1990-09-18 1991-08-13 Merck & Co., Inc. Diphosphonate intermediate for preparing an antihypercalcemic agent
US5159108A (en) 1990-09-18 1992-10-27 Merck & Co., Inc. Process for preparing an antihypercalcemic agent
CA2221844A1 (en) 1995-06-06 1996-12-12 Merck & Co., Inc. Disodium alendronate formulations
DK0833643T3 (da) * 1995-06-06 2005-05-30 Merck & Co Inc Formuleringer af vandfrit mononatriumsalt af alendronat og deres anvendelse til behandling af knoglesygdomme

Also Published As

Publication number Publication date
HUP0203078A2 (hu) 2003-01-28
US20030065214A1 (en) 2003-04-03
BR9913472A (pt) 2002-03-05
EP1107974A1 (en) 2001-06-20
EE04552B1 (et) 2005-10-17
US6281381B1 (en) 2001-08-28
EA002739B1 (ru) 2002-08-29
NO20010957L (no) 2001-04-26
JP2009143955A (ja) 2009-07-02
SI20581B (sl) 2008-06-30
AU5698899A (en) 2000-03-21
IL141423A (en) 2005-09-25
DE69932620T2 (de) 2006-12-14
HUP0203078A3 (en) 2005-01-28
SK2482001A3 (en) 2002-01-07
EA200100184A1 (ru) 2001-10-22
RO122854B1 (ro) 2010-03-30
EE200100126A (et) 2002-06-17
LT2001016A (en) 2001-10-25
KR20010079701A (ko) 2001-08-22
EP1107974A4 (en) 2001-09-26
LV12720B (en) 2002-02-20
LV12720A (lv) 2001-09-20
WO2000012517A9 (en) 2000-07-13
US6696601B2 (en) 2004-02-24
HRP20010129A2 (en) 2005-04-30
JP2002523514A (ja) 2002-07-30
IS5864A (is) 2001-02-26
DE69932620D1 (de) 2006-09-14
PT1107974E (pt) 2006-10-31
CA2341459A1 (en) 2000-03-09
YU14701A (sh) 2003-01-31
WO2000012517A1 (en) 2000-03-09
EP1107974B1 (en) 2006-08-02
ATE334993T1 (de) 2006-08-15
SI20581A (sl) 2001-12-31
IL141423A0 (en) 2002-03-10
PL346347A1 (en) 2002-02-11
KR20070034132A (ko) 2007-03-27
NO20010957D0 (no) 2001-02-26
NZ510682A (en) 2003-09-26
CZ2001629A3 (cs) 2001-08-15
LT4888B (lt) 2002-02-25
BG65329B1 (bg) 2008-02-29
BG105292A (en) 2001-12-29
ES2270613T3 (es) 2007-04-01

Similar Documents

Publication Publication Date Title
DK1107974T3 (da) Nye hydratformer af alendronat natrium, processer til fremstilling deraf, og farmaceutiske sammensætninger deraf
NO20012158L (no) Substituerte 2-fenylbenzimidazoler, fremgangsmåte til fremstilling og anvendelse derav
NO952863D0 (no) Fluoxetin-farmasöytiske sammensetninger
AU7642001A (en) Novel $G(Y) crystalline form of perindopril tert-butylamine salt, preparation method, and pharmaceutical compositions containing same.
IL151313A0 (en) Lipase containing pharmaceutical compositions
DK1233770T3 (da) Phosphonatforbindelser
DE60120691D1 (de) Zusammensetzungen zur verwendung bei der behandlung der osteoporose und/oder der entzündlichen gelenkerkrankungen
AU7641801A (en) Alpha crystalline form of perindopril tert-butylamine salt
AP2000001947A0 (en) Novel crystalline forms of an antiviral benzidazole compound.
AU7641901A (en) Novel dollar G(B crystalline form of perindopril tert- butylamine salt, preparation method, and pharmaceutical compositions containing same
NO995431D0 (no) Substituerte 3,3-diamino-2-propennitriler, deres fremstilling og anvendelse
NO20010940L (no) TAN-1057 derivater
ATE266029T1 (de) Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung
DK1372669T3 (da) Bisphosphonatholding sammensætning til forebyggelse og/eller behandling af metaboliske knoglesygdomme, fremgangsmåde til fremstilling af sådanne sammensætninger og anvendelse deraf
TR200200278T2 (tr) Kalsilitik bileşimler
DK1280812T3 (da) Cyclipostiner, fremgangsmåde til deres fremstilling og anvendelse af samme
EP1702924A3 (en) Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
DE60204721D1 (de) Herstellung von kristallinen polymorphen von fosinopril natrium
CR20120385A (es) Nuevos pirrolocarbazoles fusionados (divisional exp. 8519)